REPL

19.0700.83%
CJ

Christy J. Oliger

Independent Director

Ms. Christy J. Oliger is Independent Director of Zenas BioPharma, Inc. from September 1, 2026. She is Independent Director of Bicara Therapeutics Inc. from July 28, 2026. Ms. Oliger served as an Independent Director of Nuvalent, Inc. from June 2025 to July 15, 2026 and was its Director until June 2025. Ms. Oliger serves as Independent Director of Vera Therapeutics, Inc. since June 7, 2024. She was an Independent Director of RayzeBio, Inc. since August 2023 until February 26, 2024. She was an Independent Non-Executive Director at LAVA Therapeutics N.V. since March 09, 2023 until November 2025. She serves as Independent Director at Replimune Group, Inc. since December 1, 2021. Ms. Oliger served as Director at Reata Pharmaceuticals, Inc. since April 15, 2021 until June 2023. Ms. Oliger served as an Independent Director at Sierra Oncology, Inc. since June 02, 2021 until July 01, 2022. Ms. Oliger has been Independent Director at Karyopharm Therapeutics Inc. since August 2020. Ms. Oliger served as Vice President of Sales and Marketing Rituxan Hematology at Genentech, Inc and was its Senior Vice President, Neuroscience and Rare Disease Business Unit at Genentech from 2014 to 2017. Ms. Oliger has vast experience in the biopharmaceutical industry and is recognized for building highly effective teams, leading significant product launches and having broad therapeutic expertise serving in various commercial roles Roche Holding AG from January 2000 until July 2020. Ms. Oliger was Senior Vice President of the Oncology Business Unit at Genentech inc from January 2017 to July 2020, a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life threatening medical conditions. Ms. Oliger spent two decades with Genentech, holding a number of leadership roles including Senior Vice President, IMPACT Business Unit; Vice President, Pharma Portfolio Management; Vice President, Portfolio Planning and Vice President, Hematology Marketing and Sales, where she also held numerous senior leadership roles of increasing responsibility across a variety of therapeutic areas including oncology, neurology, rare disease, respiratory, dermatology and immunology. Prior to Genentech, Ms. Oliger held management positions at Schering Plough where she held numerous positions of increasing responsibility within the sales and marketing organization since September 1992 until December 1999. She has extensive biopharmaceutical industry experience, including various leadership roles in sales and marketing, portfolio management and overseeing multiple business units at Genentech in oncology, rare diseases, neuroscience and hematology. Ms. Oliger served as Genentechs Senior Vice President, Oncology Business Unit Head from 2017 to 2020. During her tenure at Genentech, she held senior commercial leadership roles across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology and immunology. In addition, while at Genentech Ms. Oliger held senior R&D roles, including leading the Roche global portfolio management function. Ms. Oliger served in a wide variety of commercial leadership positions at Genentech from 2000 until 2020. Ms. Oliger holds a B.A. degree in Economics from the University of California at Santa Barbara.

Positions